ERBB2 and breast cancer: Radiolabeled trastuzumab has not been delivered to BM in patients by CED, but trastuzumab infused into HER2-positive human BC tumours in the brain in athymic rats increased survival by twofold compared to intraperitoneally (i.p.)administered trastuzumab, suggesting CED improved delivery to these tumours (Grossi et al. 2003).